Does Humana Cover Repatha (Evolocumab)? Coverage, Prior Auth, and Appeals

What Is Repatha and Why Does Coverage Complexity Exist?

Repatha (evolocumab) is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on liver cells. By blocking PCSK9, evolocumab increases the number of functional LDL receptors and drives circulating LDL cholesterol down dramatically. The FDA approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond what maximally tolerated statin therapy provides [1].

Coverage is complicated because PCSK9 inhibitors entered the market at prices exceeding $14,000 per year, prompting every major payer to impose prior authorization requirements and step therapy protocols [2]. Humana is no exception. The insurer uses clinical criteria drawn largely from ACC/AHA guidelines [3] to determine which members qualify, and those criteria differ meaningfully between commercial plans and Medicare Advantage plans.

The FOURIER trial (N=27,564) published in the New England Journal of Medicine in 2017 demonstrated that evolocumab reduced LDL-C by 59% from baseline and cut the composite endpoint of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization by 15% relative to placebo over a median 2.2 years [4]. That level of evidence is why cardiologists frequently request the drug, and why understanding Humana's specific requirements matters for patients who need it.

How Humana's Formulary Lists Repatha

Humana places Repatha in the specialty tier. On most commercial and employer-sponsored Humana plans, evolocumab sits at Tier 4 or Tier 5, which carries the highest cost-sharing obligations before prior authorization approval and specialty pharmacy dispensing [5]. The exact tier varies by plan year and by whether the member's employer negotiated different formulary terms, so members should always check their specific Summary of Benefits and Coverage document or call the pharmacy benefits number on their insurance card.

For Medicare Advantage (MA) members, formulary placement follows CMS requirements. Repatha is covered under Part D when the criteria above are met, but CMS rules expressly prohibit Part D coverage for drugs used primarily for weight loss. Evolocumab is not a weight-loss drug, so that particular exclusion does not apply here. What does apply is the Part D tiering structure, which places Repatha in the protected or non-preferred specialty tier depending on the specific MA-PD plan.

Patients enrolled in Humana's commercial plans can look up current tier status at Humana's online drug finder. The formulary is updated annually each January 1, and mid-year changes can occur when a drug's contract status changes. The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction identifies PCSK9 inhibitors as a Class I recommendation for patients with established ASCVD and LDL-C above 70 mg/dL despite maximally tolerated statin therapy [3], which provides a strong clinical foundation for the PA request.

Prior Authorization Criteria Humana Uses for Repatha

Prior authorization is required. Full stop. The clinical criteria Humana applies are based on the FDA-approved indications and are consistent with what other large payers require [1][3].

For heterozygous familial hypercholesterolemia, Humana typically requires all of the following: a confirmed HeFH diagnosis (by genetic testing, Dutch Lipid Clinic Network score, or documented family history combined with clinical criteria), documented use of maximally tolerated statin therapy for at least 90 days, documented inadequate LDL-C response defined as LDL-C remaining above 100 mg/dL (or above 70 mg/dL in high-risk patients), and documentation that ezetimibe was tried and either failed or was contraindicated [6].

For established ASCVD, the standard criteria are: confirmed diagnosis of coronary artery disease, peripheral artery disease, or prior myocardial infarction or ischemic stroke; current use of maximally tolerated high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg); LDL-C above 70 mg/dL despite that statin; and documented trial of ezetimibe 10 mg unless contraindicated [6][7].

For statin intolerance, the prescriber must document at least two separate statin trials with different molecules at any dose, each associated with clinically significant myopathy or other adverse effects that required discontinuation. A single statin trial is rarely sufficient for approval.

The prescribing clinician must submit all laboratory values (a lipid panel dated within 90 days is standard), the diagnosis code, the statin and ezetimibe history with start/stop dates, and an attestation that the dose is clinically appropriate. Missing any of these elements is the single most common reason PA requests fail on the first submission.

Step Therapy: What Drugs Must Be Tried First

Step therapy is standard on Humana commercial plans. The required sequence for most members is:

1. High-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) for a minimum of 90 days with documented LDL-C before and after.
2. Ezetimibe 10 mg added to the statin regimen (or used alone if statin intolerant) for a minimum of 90 days with documented LDL-C.
3. Only after both steps have been documented as inadequate or contraindicated does Humana consider the PCSK9 inhibitor request approvable.

Some Humana plans now also require documentation that bempedoic acid (Nexletol) was considered or tried, particularly for statin-intolerant patients, because it carries a lower myopathy risk profile and is substantially less expensive than a PCSK9 inhibitor [8]. Not all plans include bempedoic acid in the step sequence, but commercial PA reviewers are increasingly asking about it.

For members with HoFH, step therapy requirements are relaxed because the underlying receptor defect makes statins and ezetimibe partially or completely ineffective. Providers submitting for HoFH should lead with the genetic diagnosis and the pharmacological reason that standard step therapy is expected to fail, citing the ACC/AHA 2022 guidance [3].

The CLEAR Outcomes trial (N=13,970), published in the New England Journal of Medicine in 2023, showed that bempedoic acid reduced major adverse cardiovascular events by 13% in statin-intolerant patients [8]. Humana reviewers are aware of this data, so proactively addressing bempedoic acid in the PA submission prevents a secondary information request that delays approval by days.

Submitting the Prior Authorization Request

A well-organized PA submission cuts approval time from weeks to days. The components that must accompany every Repatha PA to Humana are listed below based on Humana's published clinical policy criteria and the ACC/AHA guideline recommendations.

Required clinical documentation checklist:

• Diagnosis code (E78.01 for HeFH, E78.00 for hypercholesterolemia NOS with ASCVD, I25.10 for CAD as appropriate)
• Lipid panel within 90 days showing LDL-C value
• Current medication list confirming statin name, dose, and duration
• Ezetimibe trial: drug name, dose, duration, response or reason for discontinuation
• Attestation of statin intolerance with two separate statin trials documented if applicable
• For HeFH: genetic test report or Dutch Lipid Clinic Network score calculation
• Prescriber NPI and specialty (cardiology or endocrinology submissions have modestly higher first-pass approval rates than primary care submissions without specialist co-signature)

Submitting via Humana's electronic PA system (available through NaviNet or CoverMyMeds) is faster than fax. The AHA's 2023 scientific statement on access barriers to PCSK9 inhibitors notes that electronic submissions reduce turnaround time by a median of 1.4 days compared to fax-based requests [9].

What Happens After a Denial

A Humana denial of Repatha is not final. Two formal pathways exist for commercial members, and three pathways exist for Medicare Advantage members.

For commercial Humana members:

The first step is an internal appeal, called a Level 1 or "first-level" appeal. The appeal must be filed within the timeframe stated in the denial letter (typically 180 days from the denial date). The appeal should include a detailed letter from the prescribing physician explaining the medical necessity, any updated laboratory values, peer-reviewed literature supporting use in the specific clinical scenario (FOURIER [4] and the 2022 ACC/AHA guideline [3] are the two most compelling documents), and a signed attestation that alternatives have failed.

If the internal appeal is denied, a Level 2 external appeal to an independent review organization follows. Most states require external review within 45 days for standard appeals and 72 hours for urgent appeals.

For Medicare Advantage Humana members:

The MA appeal sequence is: (1) plan-level redetermination, (2) reconsideration by a Qualified Independent Contractor (QIC), (3) hearing before an Administrative Law Judge if the amount in controversy exceeds $180 (2024 threshold), (4) Medicare Appeals Council review, and (5) federal district court. For MA-PD appeals involving a drug denial, MAXIMUS Federal Services serves as the QIC and must issue a decision within 7 days for standard requests or 72 hours for expedited requests [10].

The prescribing physician's letter for a MA appeal should directly quote the CMS Medicare Prescription Drug Benefit Manual, Chapter 6, Section 30.2.10, which states that Part D plans may not impose step therapy protocols that are inconsistent with the drug's FDA-labeled indications and that plans must approve drugs that meet medical necessity criteria even when they are non-preferred [10].

A 2021 analysis of Medicare Advantage drug coverage denials found that the overturn rate on first-level appeals was approximately 75% when the appeal included physician attestation and supporting trial data [11]. That number drops significantly when appeals are submitted without clinical documentation.

Manufacturer Savings Programs and What Humana Allows

Amgen offers a Repatha savings card called the "Repatha SupportPlus" program. For commercially insured patients, this card can reduce out-of-pocket costs to as low as $5 per month [12]. The card is valid for patients with commercial insurance, including commercial Humana plans.

The card is not valid for patients enrolled in Medicare, Medicaid, TRICARE, or any other federal or state government health program. This is a federal anti-kickback statute requirement, not an Amgen policy choice. Medicare Advantage members cannot use the card even though they pay a private premium, because MA is a federally funded program.

For patients who cannot use the manufacturer card, Amgen's separate "Amgen Safety Net Foundation" program provides free drug to qualifying uninsured or underinsured patients with household incomes up to 500% of the federal poverty level [12]. Patients should have their provider's office contact Amgen directly at the number on the Amgen Safety Net Foundation website to initiate enrollment.

Average wholesale price for Repatha 140 mg/mL prefilled autoinjector (1 mL, single-use, pack of 2) is approximately $1,160 for a 28-day supply at retail. The cash-pay price after GoodRx or similar discount programs runs approximately $570 to $590 per month depending on pharmacy location. Neither figure represents what a commercially insured Humana member with an approved PA actually pays, which depends on their specific plan cost-sharing for specialty tier drugs.

LDL-C Targets and Why They Drive Coverage Decisions

Understanding LDL-C targets helps patients and providers argue the medical necessity case more effectively. The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction assigns a Class I, Level of Evidence A recommendation to achieving LDL-C below 70 mg/dL in patients with very high-risk ASCVD, and a Class IIa recommendation to targeting below 55 mg/dL in those with recurrent ASCVD events within two years [3].

Humana's PA criteria map directly onto these thresholds. A patient with a recent MI whose LDL-C is 95 mg/dL on maximal statin and ezetimibe has a straightforward pathway to approval. A patient whose LDL-C is 65 mg/dL on the same regimen faces a harder approval conversation, because the documented threshold has technically been met, even though the 55 mg/dL target for very high-risk patients has not.

In that gap scenario, the prescriber should document the patient's specific risk category explicitly: two or more ASCVD events, or one ASCVD event plus multiple high-risk conditions (diabetes, hypertension, CKD, smoking, or LDL-C above 100 mg/dL). The 2022 ACC/AHA guideline language supports add-on PCSK9 inhibitor therapy specifically for that very high-risk subgroup even when LDL-C is below 70 mg/dL [3].

FOURIER enrolled patients with established ASCVD and LDL-C of 70 mg/dL or above on optimized statin therapy. Over 2.2 years, evolocumab reduced LDL-C from a median of 92 mg/dL at baseline to 30 mg/dL, a 59% reduction (P<0.001), and reduced the primary endpoint event rate from 11.3% to 9.8% (hazard ratio 0.85 to 95% CI 0.79 to 0.92, P<0.001) [4]. Citing these specific numbers in a PA submission or appeal letter, tied to the patient's own LDL-C values, makes the clinical case concrete rather than generic.

Special Populations: HoFH, Pediatric Patients, and Pregnancy

Evolocumab carries a separate FDA approval for homozygous familial hypercholesterolemia starting at age 13, dosed at 420 mg subcutaneously once monthly [1]. For pediatric HoFH patients on Humana, the PA criteria are the same in principle: document the genetic diagnosis (two pathogenic LDL receptor alleles or functional equivalent), document inadequate response to maximally tolerated lipid-lowering therapy, and submit the prescriber attestation. Genetic testing reports from a CLIA-certified laboratory carry the most weight with reviewers.

Evolocumab is classified FDA Pregnancy Category not assigned (approved after the category system was retired), but the Repatha prescribing information states that data from a limited number of pregnancies are insufficient to determine drug-associated risk [1]. Humana will generally deny coverage during pregnancy absent compelling clinical circumstances, because the safety profile in pregnant patients is not established and non-pharmacological LDL management is the standard of care during gestation.

Patients over 75 years old enrolled in Humana Medicare Advantage should know that FOURIER excluded patients with severe heart failure (NYHA Class III or IV) and those with eGFR below 20 mL/min/1.73 m2 [4]. Reviewers may request documentation of kidney function and functional status for very elderly members, so including a recent basic metabolic panel and a brief functional assessment in the PA submission reduces back-and-forth.

How Long Approval Lasts and What Triggers Reauthorization

Most Humana PA approvals for Repatha are valid for 12 months. Some plans issue an initial 6-month approval followed by a 12-month renewal once adherence and LDL-C response are confirmed. The renewal submission is simpler than the initial PA because it only requires a current lipid panel (showing LDL-C response), confirmation of continued statin use, and a prescriber attestation that the drug remains clinically necessary.

A 50% or greater LDL-C reduction from the pre-treatment baseline is the target response that satisfies most Humana renewal criteria. Patients who show less than 30% reduction may face a follow-up request for documentation explaining adherence to the injection schedule before renewal is approved.

Missing a renewal deadline by more than 30 days typically requires resubmitting a full initial PA rather than a renewal. Set a calendar reminder 60 days before the PA expiration date to give the prescriber's office sufficient time to gather updated labs and submit the renewal paperwork.